Harm caused by the use of lisdexamfetamine to increase the academic performance of medical students: integrative review

Author:

Bacos Beatriz Gordilho,Bergamini Valentina Colombo,Rodrigues Frank Menezes,Marini Danyelle Cristine,Alves dos Santos Cleidivan,Almeida Viana Bianca Lorayne de,Vasconcelos Ana Paula de,Rodrigues Francisco Sandro Menezes

Abstract

Lisdexamfetamine (LIS) is a central nervous system stimulant used to treat Attention-deficit/hyperactivity disorder (ADHD), improving attention, concentration and reducing hyperactivity. However, it is important to highlight that the National Health Surveillance Agency (ANVISA), the regulatory body for medicines in Brazil, does not recognize the efficacy and safety of LIS outside of its indications contained in the medicine leaflet and, in addition, the inappropriate use of this substance becomes a risk factor for the occurrence of anxiety, cardiac arrhythmias and glaucoma. This is an integrative literature review carried out in PubMed, LILACS and SciELO databases searching the descriptors “Lisdexamfetamine”, “ADHD”, and “Students”. Around 23.3% of medical students use these substances to overcome fatigue and improve performance, with Ritalin and Venvanse being the most common. However, 57.1% use these medications without a prescription or diagnosis of ADHD, obtaining them illegally. In general, all medications should only be used after medical evaluation and verification of real need, however, in the case of psychostimulants, caution must be even greater. Therefore, it is crucial to raise awareness among patients who are not diagnosed with ADHD about the long and short-term implications of self-medication with LIS, seeking to combat this public health problem.

Publisher

Editora Alumniin

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3